These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 12150818)

  • 1. A genome-based strategy uncovers frequent BRAF mutations in melanoma.
    Pollock PM; Meltzer PS
    Cancer Cell; 2002 Jul; 2(1):5-7. PubMed ID: 12150818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutations of the BRAF gene in human cancer.
    Davies H; Bignell GR; Cox C; Stephens P; Edkins S; Clegg S; Teague J; Woffendin H; Garnett MJ; Bottomley W; Davis N; Dicks E; Ewing R; Floyd Y; Gray K; Hall S; Hawes R; Hughes J; Kosmidou V; Menzies A; Mould C; Parker A; Stevens C; Watt S; Hooper S; Wilson R; Jayatilake H; Gusterson BA; Cooper C; Shipley J; Hargrave D; Pritchard-Jones K; Maitland N; Chenevix-Trench G; Riggins GJ; Bigner DD; Palmieri G; Cossu A; Flanagan A; Nicholson A; Ho JW; Leung SY; Yuen ST; Weber BL; Seigler HF; Darrow TL; Paterson H; Marais R; Marshall CJ; Wooster R; Stratton MR; Futreal PA
    Nature; 2002 Jun; 417(6892):949-54. PubMed ID: 12068308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SPRY2 is an inhibitor of the ras/extracellular signal-regulated kinase pathway in melanocytes and melanoma cells with wild-type BRAF but not with the V599E mutant.
    Tsavachidou D; Coleman ML; Athanasiadis G; Li S; Licht JD; Olson MF; Weber BL
    Cancer Res; 2004 Aug; 64(16):5556-9. PubMed ID: 15313890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. C-Raf inhibits MAPK activation and transformation by B-Raf(V600E).
    Karreth FA; DeNicola GM; Winter SP; Tuveson DA
    Mol Cell; 2009 Nov; 36(3):477-86. PubMed ID: 19917255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different effects of point mutations within the B-Raf glycine-rich loop in colorectal tumors on mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase and nuclear factor kappaB pathway and cellular transformation.
    Ikenoue T; Hikiba Y; Kanai F; Aragaki J; Tanaka Y; Imamura J; Imamura T; Ohta M; Ijichi H; Tateishi K; Kawakami T; Matsumura M; Kawabe T; Omata M
    Cancer Res; 2004 May; 64(10):3428-35. PubMed ID: 15150094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The T1796A mutation of the BRAF gene is absent in Spitz nevi.
    Palmedo G; Hantschke M; Rütten A; Mentzel T; Hügel H; Flaig MJ; Yazdi AS; Sander CA; Kutzner H
    J Cutan Pathol; 2004 Mar; 31(3):266-70. PubMed ID: 14984580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppression of BRAF(V599E) in human melanoma abrogates transformation.
    Hingorani SR; Jacobetz MA; Robertson GP; Herlyn M; Tuveson DA
    Cancer Res; 2003 Sep; 63(17):5198-202. PubMed ID: 14500344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncogenes in melanoma.
    Polsky D; Cordon-Cardo C
    Oncogene; 2003 May; 22(20):3087-91. PubMed ID: 12789285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation.
    Satyamoorthy K; Li G; Gerrero MR; Brose MS; Volpe P; Weber BL; Van Belle P; Elder DE; Herlyn M
    Cancer Res; 2003 Feb; 63(4):756-9. PubMed ID: 12591721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas.
    Reifenberger J; Knobbe CB; Sterzinger AA; Blaschke B; Schulte KW; Ruzicka T; Reifenberger G
    Int J Cancer; 2004 Apr; 109(3):377-84. PubMed ID: 14961576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of Raf activity by dimerization.
    Wei H; Zhou MM
    Pigment Cell Melanoma Res; 2010 Apr; 23(2):156-7. PubMed ID: 20067555
    [No Abstract]   [Full Text] [Related]  

  • 12. A pivotal role for ERK in the oncogenic behaviour of malignant melanoma?
    Smalley KS
    Int J Cancer; 2003 May; 104(5):527-32. PubMed ID: 12594806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RAF proteins exert both specific and compensatory functions during tumour progression of NRAS-driven melanoma.
    Dorard C; Estrada C; Barbotin C; Larcher M; Garancher A; Leloup J; Beermann F; Baccarini M; Pouponnot C; Larue L; Eychène A; Druillennec S
    Nat Commun; 2017 May; 8():15262. PubMed ID: 28497782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRAF and RAS mutations in human lung cancer and melanoma.
    Brose MS; Volpe P; Feldman M; Kumar M; Rishi I; Gerrero R; Einhorn E; Herlyn M; Minna J; Nicholson A; Roth JA; Albelda SM; Davies H; Cox C; Brignell G; Stephens P; Futreal PA; Wooster R; Stratton MR; Weber BL
    Cancer Res; 2002 Dec; 62(23):6997-7000. PubMed ID: 12460918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma.
    Tsao H; Goel V; Wu H; Yang G; Haluska FG
    J Invest Dermatol; 2004 Feb; 122(2):337-41. PubMed ID: 15009714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microarray expression profiling in melanoma reveals a BRAF mutation signature.
    Pavey S; Johansson P; Packer L; Taylor J; Stark M; Pollock PM; Walker GJ; Boyle GM; Harper U; Cozzi SJ; Hansen K; Yudt L; Schmidt C; Hersey P; Ellem KA; O'Rourke MG; Parsons PG; Meltzer P; Ringnér M; Hayward NK
    Oncogene; 2004 May; 23(23):4060-7. PubMed ID: 15048078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Steroid receptor fusion proteins for conditional activation of Raf-MEK-ERK signaling pathway.
    McMahon M
    Methods Enzymol; 2001; 332():401-17. PubMed ID: 11305114
    [No Abstract]   [Full Text] [Related]  

  • 18. Selection of established tumour cells through narrow diameter micropores enriches for elevated Ras/Raf/MEK/ERK MAPK signalling and enhanced tumour growth.
    Rudzka DA; Mason S; Neilson M; McGarry L; Kalna G; Hedley A; Blyth K; Olson MF
    Small GTPases; 2021 Jul; 12(4):294-310. PubMed ID: 32569510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of metastatic melanoma with an orally available inhibitor of the Ras-Raf-MAPK cascade.
    Collisson EA; De A; Suzuki H; Gambhir SS; Kolodney MS
    Cancer Res; 2003 Sep; 63(18):5669-73. PubMed ID: 14522881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRAF as a potential therapeutic target in melanoma and other malignancies.
    Tuveson DA; Weber BL; Herlyn M
    Cancer Cell; 2003 Aug; 4(2):95-8. PubMed ID: 12957284
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.